Yakup Ergün
@dr_yakupergun
Followers
3,404
Following
331
Media
783
Statuses
1,605
Medical Oncologist / Bower Hospital / Exploring Evidence-Based Approaches in Cancer | #bcsm #crcsm #lcsm #cancer
Turkey
Joined December 2012
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Israel
• 5383105 Tweets
Iran
• 3331517 Tweets
Vance
• 1896840 Tweets
Vance
• 1896840 Tweets
The VP
• 307802 Tweets
Moderators
• 247074 Tweets
Minnesota
• 114027 Tweets
Pence
• 109899 Tweets
Margaret
• 100618 Tweets
Tampon Tim
• 89128 Tweets
#WWENXT
• 79690 Tweets
Tiananmen Square
• 58251 Tweets
からくりサーカス
• 51014 Tweets
ケンタッキー
• 42352 Tweets
Knucklehead
• 39733 Tweets
#原神KFCコラボ
• 32735 Tweets
Megyn
• 31692 Tweets
महात्मा गांधी
• 31545 Tweets
#GandhiJayanti
• 29560 Tweets
Amber Thurman
• 28620 Tweets
गांधी जयंती
• 26644 Tweets
लाल बहादुर शास्त्री
• 25735 Tweets
Obamacare
• 23331 Tweets
Timmy
• 21538 Tweets
Aces
• 21197 Tweets
ブリーダーズカップ
• 20130 Tweets
Shapiro
• 16878 Tweets
#マックのコーヒー記念カキコ
• 15816 Tweets
ニンテンドーミュージアム
• 15027 Tweets
Gago
• 14876 Tweets
ネットオーダー
• 13922 Tweets
Homely Shelter
• 12743 Tweets
宮崎空港
• 11872 Tweets
原神コラボ
• 10492 Tweets
Pinned Tweet
Can we truly label a study with Grade 5 toxicity as 'acceptable' or 'manageable'?
My letter on the necessity of "redefining toxicity terminology in clinical trial reporting" (original title)👇
@OncoAlert
4
30
102
@historyinmemes
A tragic story highlighting the importance of understanding complex medical conditions. It's relieving to know that justice prevailed in the end. A lesson to be learned from this incident.
5
13
558
@ovgunaercan
Sayın hocam ben bir hekim olarak branşım olmadığı için acil tıbbi müdahale konusunda yorum yapmaktan imtina ediyorum, belki yanlış bilgi veririm diye. İyi niyetinizden şüphem yok ama tıbbi durumlar ile bilgilendirmeleri ilgili branşın hekimlerine bırakırsak daha uygun olacaktır.
1
2
345
#ASCO23
D-TORCH: Topical diclofenac in prevention of hand-foot syndrome in pts receiving capecitabine
💥Topical diclofenac is effective in preventing all grades of HFS in patients receiving capecitabine
New standard of care to prevent capecitabine associated HFS?
@OncoAlert
11
146
300
Adjuvant chemotherapy recommendations for stage II colon cancer:
Joint chart of
@ASCO
and
@myESMO
guidelines
@TotalHealthConf
@oncotwitts
@OncoAlert
7
107
271
#ASCO24
Treatment Selection and Sequencing in Breast Cancer👇
From the wonderful presentation by Dr. Ana Christina Garrido-Castro
@OncoAlert
3
104
271
@historyinmemes
The vaccine is the most important health discovery in human history. Trust science..
10
6
252
Why do patients with cancer die?
An excellent review on the direct and indirect causes of cancer-related deaths👇
📌Fully understanding these causes can provide an opportunity to reduce deaths
@OncoAlert
2
80
243
Management of Locally Advanced Rectal Cancer: ASCO Guideline
🔹️Timing of Chemotherapy
🔹️Total Neoadjuvant Therapy
🔹️Nonoperative Management
🔹️Immunotherapy
@OncoAlert
2
117
240
@historyinmemes
Discovering the essence of civilization through a healed bone is a testament to remarkable insight and profound wisdom.
1
7
232
Omission of 5-FU Bolus From Multidrug Regimens
🔍Retrospective study with ~12,000 pts in GI cancer
💥Omitting 5-FU bolus had no negative impact on survival (FOLFOX, FOLFIRI, FOLFIRINOX)
💥Associated with a significant reduction in toxicity
5
90
234
Efficacy of first-line treatment options in advanced EGFR-mutated NSCLC
From Stephanie P. L. Saw's presentation at
#ASCO24
@OncoAlert
1
73
211
Management of Stage III NSCLC: ASCO Rapid Recommendation Update
💥Patients with unresectable stage III NSCLC with an EGFR exon 19 deletion or exon 21 L858R mutation may be offered consolidation osimertinib after definitive CRT (LAURA)
@OncoAlert
0
73
201
1
66
196
Tumor biomarkers for diagnosis, prognosis and targeted therapy
✒️This is the most comprehensive review I have seen so far (I can't say I've read it yet).
Number of pages: 86
Number of references: 1387
🗯In fact, it's more like a book than a review. Congrats to the authours.
3
76
194
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases : SENOMAC trial
"In clinically node-negative patients with sentinel lymph node biopsy showing macrometastasis (1 or 2), comprehensive ALND can be omitted"
@OncoAlert
5
87
192
6th and 7th International Consensus Guidelines for the management of advanced breast cancer (ABC Guidelines 6 and 7)
💥A guide where we can find answers to every question about aBC👇
@OncoAlert
#bcsm
3
95
190
#ASCO24
CROWN study: lorlatinib vs crizotinib
Lorlatinib..... no need to comment,
look at the curves👇
Presented by Dr.
@bensolomon1
👏👏
@OncoAlert
4
68
190
Treating cancer-associated venous thromboembolism: a practical approach
💥A great review that takes into account cancer types, comorbid diseases, and drug-drug interactions, offering practical approaches👇
@OncoAlert
2
90
186
PRODIGE 23: Long-term results
Neoadj FOLFIRINOX vs SoC (CRT)
7y-DFS➡️67.6 vs 62.5%✅️
7y-MFS➡️79.2 vs 72.3%✅️
7y-OS➡️81.9 vs76.1%✅️✅️
💥Induction chemotherapy with mFOLFIRINOX improves OS in LARC patients
@OncoAlert
3
87
184
From the ESMO "cancer of unknown primary" management guideline; Recommended IHC markers for differential diagnosis👇
1
70
181
Breast cancer highlights from 2023: Knowledge to guide practice and future research
📌PubMed has 15,000 publications on BC in 2023.
The authors have summarized the most important studies
A great review👇
#bcsm
2
67
179
#ESMO24
HR-positive breast cancer treatment algorithm
From Dr. Lucia Del Mastro's excellent presentation👇
0
71
175
#ASCO24
DESTINY-Breast07: T-DXd and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC (phase 1b/2)
First-line!!!!
ORR
T-DXD➡️76%
T-DXd +P➡️84%
1y PFS➡️80.8% and 89.4%
Presented by Prof
@FAndreMD
@OncoAlert
0
70
173
#ASCO24
Current HER2+ mBC treatment algorithm
T-DXd is close to becoming first-line (DB09).
From Dr. Ciara Catherine O'Sullivan's excellent discussion👇
@OncoAlert
0
74
172
Management of Locally Advanced Rectal Cancer: ASCO Guideline Clinical Insights
📌The article addresses the challenges clinicians may face in applying the ASCO guidelines for the management of locally advanced rectal cancer
1
67
173
5
56
168
@DrSarperSaglam
Bu kitabı elime aldığım günden beri ders çalışıyorum. Acaba bitirmesek daha mı iyi olacaktı🤔
3
0
163
Biomarkers, Molecular Targets, and Methods of Detection for Precision Medicines in NSCLC
(ESMO guideline)
0
55
164
Neoadjuvant Pembrolizumab in Localized MSI-H/dMMR Solid Tumors
@JCO_ASCO
🔹Phase 2, 35 pts (27 CRC)
ORR➡️82%
☑️pCR 65% (17 pts underwent surgery)
💥Tissue-agnostic therapy become the new standard for the neoadjuvant setting?
@OncoAlert
0
74
157
Platinum‐based chemotherapy for early triple‐negative breast cancer (Cochrane Database)
20 studies, 4.688 patients
DFS and OS (Carbo)⬆️
Neoadj➡️HR: 0.63 and 0.69
Adj➡️HR 0.69 and 0.70
📌 Regardless of BRCA, HRD, LN positivity and anthracycline
2
74
155
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative eBC: Evidence and Controversies
📌Increasing adjuvant treatment options in HER2-neg eBC are causing confusion.
💥This topic is discussed in this excellent review👇
@OncJournal
@OncoAlert
2
65
154
Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline
Who, when and which genetic test?
@OncoAlert
1
83
152
HER2-targeted therapies beyond breast cancer — an update
💥HER2-targeted therapies are expanding across various solid tumors, with new combinations and novel agents being investigated to overcome resistance mechanisms
An excellent review👇
@OncoAlert
1
59
150
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline
@ASCO
@JCO_ASCO
@OncoAlert
1
59
147
Comparison of HER2-Zero and HER2-Low in terms of clinicopathological factors and survival in early-stage breast cancer: A Systematic Review and Meta-analysis
Our meta-analysis is out now👇
1/3
@OncoAlert
@OncBrothers
@curijoey
@stolaney1
@PTarantinoMD
4
46
149
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
@myESMO
@Annals_Oncology
0
59
148
New promises and challenges in the treatment of advanced non-small-cell lung cancer
💥An excellent review👇
@OncoAlert
2
55
150
Proton pump inhibitors and cancer treatments: Emerging evidence against coadministration
💥We should not overlook the effect of PPIs, which are frequently used in routine practice, on anticancer drugs.
A great review👇
@OncoAlert
1
56
148
💥This retrospective study finds that endocrine and cutaneous irAEs in immunotherapy recieved patients are linked to better survival, while respiratory and neurological irAEs predict unfavourable outcomes
@OncoAlert
1
54
147
1
38
143
#ASCO24
Efficacy of T-DXd according to different tumor and HER2 levels
From Prof.
@curijoey
excellent presentation
@OncoAlert
0
51
142
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update
0
53
139
Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline
🔹️ BRCA1/2 testing recommended for newly diagnosed breast cancer patients aged ≤65 and select cases >65
🔹️ Recurrent breast cancer patients eligible for PARP inhibitor therapy
2
65
139
ASCO Educational Book
Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between
@ASCO
@OncoAlert
1
58
137
Systemic Therapy for Melanoma: ASCO Guideline Update Q and A
.
2
57
135
ESMO Expert Consensus Statements on the management of breast cancer during pregnancy 👇
0
56
137
Final results of RIGHT Choice: Ribociclib plus ET vs ChT in premenopausal women with clinically aggressive HR+/HER2− aBC
🔍47.7% patients had investigator-assessed visceral crisis
R+ET vs ChT
mPFS➡️21.8 vs 12.8 mo
ORR➡️66.1% vs 61.8%
@OncoAlert
2
65
135
Recommendations for the use of NGS for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
✅️ESMO expands tumour NGS recommendations to include BC, GIST, thyroid cancer, and CUP
@OncoAlert
#precisionmedicine
1
51
135
Updated treatment recommendations for prostate cancer (ESMO)
💥Updated guideline with current results of treatment options such as triple combinations, PARP inhibitors, Lu-177👇
@myESMO
@Annals_Oncology
@OncoAlert
0
58
135
Treatment algorithms in mBC👇
From the
#ASCO23
and
#ESMOBreast23
presentations
HR+/HER2- by Dr.
@StoverLab
HER2+ by Dr. Shanu Modi
@OncoAlert
1
63
132
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
@myESMO
@Annals_Oncology
@OncoAlert
0
61
134
#ASCO24
5-Year Outcomes From the Phase III CROWN Study
💥Great results for Lorlatinib.
The mPFS has not yet been reached in the median 5-year FU.
5y PFS➡️60%‼️
@bensolomon1
@OncoAlert
1
43
130
Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines
@OncoAlert
1
53
132
Just published! Our study on G-CSF prophylaxis in extensive-stage SCLC with chemoimmunotherapy
💥G-CSF didn’t significantly impact response rates, PFS, or OS
💥 Grade 3-4 AEs were comparable between the G-CSF and non-G-CSF groups
@OncoAlert
5
38
132
NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024
For many years, patients with rectal cancer have undergone radiotherapy and inevitably surgery, enduring the associated toxicities, with some having to live with a permanent colostomy. However, recent studies have shown
1
61
133
Oxaliplatin in Adjuvant Colorectal Cancer: Is There a Role in Older Patients?
🔍Five RCTs, 1.985 pts
💥No benefit in adding adjuvant oxaliplatin (HR:1.02)
@JCO_ASCO
@OncoAlert
2
45
131
NORPACT-1 trial: Neoadjuvant FOLFIRINOX versus upfront surgery for resectable PDAC
FOLFIRINOX vs Surgery
mOS➡️25.1 vs 38.5 mo
💥This trial did not show a survival benefit from neoadjuvant FOLFIRINOX in resectable PDAC compared with upfront surgery
4
42
129
MONARCH 3: Final overall survival results
🔍mFU: 8.1 years (OS: secondary endpoint)
mOS➡️66.8 vs 53.7 mo (HR:0.8, p:0.06)
💥The absolute difference was 13.1 months but did not reach statistical significance
@Annals_Oncology
@OncoAlert
2
48
128
#ESMO24
Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2
🔍One dose of ipilimumab and two doses of nivolumab prior to surgery, 64% had cT4 tumors.
3-year DFS➡️💯%
Presented by
@MyriamChalabi
5
40
128
#ASCO24
Early-Stage Rectal Cancer: Is There a Best Approach?
From the perspective of Dr. Benjamin A. Weinberg👇
1
52
127
Lifetime Cancer Risks in ''Hereditary Breast and Ovarian Cancer'' associated pathogenic variants👇
From
@myESMO
guide
0
59
127
@ASCO
NSCLC Guideline updates👇
Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline, Version 2023.3
Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline, Version 2023.3
1
62
125
Oxaliplatin Addition to Adjuvant ChT in High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis
💥In high-risk stage II CC, adding oxaliplatin to FP does not provide any benefit in terms of OS
❗️An analysis based on MSI status and T4a/b was not performed
1
58
125
Management of infusion-related reactions in cancer therapy: strategies and challenges
0
86
121
#ESMO24
KEYNOTE-522: Final OS results
mFU: 75 mo
5-y EFS➡️81.2% vs 72.2% (Δ 9%)
5-y OS➡️86.6% vs 81.7% (HR: 0.66)
pCR: Δ 0.7%
Npn-pCR: Δ 6.1%
Is there a need for adjuvant pembro in pCR?
4
43
123
Optimal Adjuvant CDK 4/6 Inhibitors in early BC: ASCO Guideline Update
💥For patients who meet the eligibility criteria of the studies, adjuvant abemaciclib is strongly recommended, while ribociclib is currently conditionally recommended
@OncoAlert
1
51
123
Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management
✨️All about TKI toxicities
An excellent review that should be on the reading list👇
0
42
122
Long-term outcomes by lobular vs ductal histology in four NSABP adjuvant BC trials
📌Patientts with ILC were older, had larger and more frequent ER-positive tumors, and more positive LN
📌Compared to NST (ductal) pts, those with ILC had a higher risk of late recurrence and
4
54
122
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
💥PFS and OS X2️⃣
0
47
120
Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival
💫Great article about an argument that will never end.
@JCO_ASCO
0
58
120
In HER2+ BC, the decision for PMRT should be made according to the node status at the time of diagnosis or according to the pathological stage after neoadjuvant therapy?
312 pts N+➡️55% ypN0
5y LRRFS👇
PMRT vs No-PMRT
ypNO➡️97 vs 97%
ypN1➡️85 vs 89%
ypN2-3➡️92 vs 75%❗️
0
60
119
MMR and MSI Testing for ICI Therapy: ASCO Endorsement of College of American
@Pathologists
Guideline
🔹CRC➡️IHC and/or PCR or NGS
🔹GE and SB➡️IHC and/or PCR
🔹Endometrium➡️IHC
🔸TMB should not be used as a surrogate for dMMR
@ASCO
@JCO_ASCO
@OncoAlert
0
47
115
ESMO Recommendations on clinical reporting of genomics test results for solid cancers
Recommendations on structured genomic reports to guide therapy selection in solid cancers, improve physician decision-making, and enhance patient outcomes👇
@OncoAlert
0
36
116
#ESMO24
Impact of lean body mass-based oxaliplatin dosage on neurotoxicity in adjuvant treatment of stage III colorectal cancer: Final results of the phase II randomized LEANOX trial
💥Oxaliplatin dosing based on lean body mass reduces neuropathy without compromising survival
3
42
116
Safety profile T-DM1 with concurrent radiation therapy: a meta-analysis
Brain RT + T-DM1
❗️Radionecrosis➡️17%
Adjuvan RT + T-DM1
✅️Pneumonitis➡️<1%
✅️Skin toxicity➡️1%
📌Adjuvant RT concurrent T-DM1 appears safe
@RadiotherapyOn1
@OncoAlert
0
59
115
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer
💥Excellent review and treatment algorithm👇
@OncoAlert
0
41
115
@historyinmemes
Displaying cultural superiority is intolerant and unsettling. Leave these people alone...
2
1
107
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
A great review for weekend reading👇
0
30
111
Excited to share our meta-analysis
💥According to the pooled analysis of the PENELOPE-B, PALLAS, MonarchE and NATALEE trials, there is a significant DFS benefit of CDK 4/6 inhibition, especially in stage 3 patients (HR: 0.67)
3
52
112
My comment on Common Sense Oncology: We are all responsible
✨️Physicians should stand in the light of unbiased science, not under the influence of the pharmaceutical industry, to advocate for patients' rights.
@TheLancetOncol
4
27
110
The antibody–drug conjugate landscape
💥A great mini-review of ADC development, showcasing advancements in targets, drugs, antibodies, linkers, and conjugation methods👇
0
31
111
💥HER2-expression in HER2-negative tumors follows a dynamic process
💥In this study, changes in HER2 status were observed in 37.3% of relapses
💥The incidence of HER2-Low is higher in advanced tumors (45%➡️50%)
💥Conversion from HER2-Zero to HER2-Low was observed more in the
1
37
110
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development
0
50
110
2023 MASCC and ESMO guideline update for the prevention of chemotherapy and radiotherapy induced nausea and vomiting
@myESMO
@ESMO_Open
0
64
106
Therapy for Stage IV Non–Small Cell Lung Cancer With and Without Driver Alterations: ASCO Living Guideline Clinical Insights
@JCOOP_ASCO
@OncoAlert
1
49
108
Real-world overall survival after alternative dosing for pembrolizumab in the treatment of NCSLC
💥In this RWD involving 1996 patients, low-dose pembrolizumab significantly reduces costs without compromising efficacy
4
28
107
Cancer statistics, 2️⃣0️⃣2️⃣3️⃣
⬇️Cancer death rates continue to decline
⬆️The incidence of breast, prostate and endometrial cancer is increasing
@CAonline
@oncoalert
0
40
105
PAPILLON: Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
0
46
104
According to our last meta-analysis in which we examined the effect of HER2-Low status on pCR and survival in eTNBC;
🔍12 studies, 4.094 patients
pCR➡️similar (40% vs 38%)
DFS and OS➡️better on HER2-Low
@CBCjournal
@OncoAlert
2
29
105
